Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

"The most striking finding," said George M. Gill, MD, Oncolytic's Senior VP of Clinical and Regulatory Affairs, "is that in nine evaluable late-stage head and neck cancer patients, eight of whom have refractory disease, four had durable partial responses and four others showed stable disease for periods of two, five plus, and eight cycles."

Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response. These results appear to confirm preclinical evidence of synergy for REOLYSIN(R) and platinum/taxane combinations. A U.S. Phase 2 trial has now been opened in this patient population utilizing this regimen.

Fourteen patients have been treated to date in the Phase I and Phase II (REO 011) trials. The detailed results are summarized in the following table:

-------------------------------------------------------------------------

REOLYSIN

Primary Tumour Dose TCID(50) Cycles Best Response

-------------------------------------------------------------------------

Phase I patients

-------------------------------------------------------------------------

Melanoma 3x10(9) 2 PD

-------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... FL (PRWEB) November 14, 2014 ... scientifically validated physical activity and sleep measurement platform ... improved subject experience along with multiple new channels ... and secondary accelerometer. Equipped with Bluetooth Smart technology, ... capture and mobile data uploads to ActiGraph’s cloud-based ...
(Date:11/15/2014)... Denver, Colorado (PRWEB) November 14, 2014 ... leading provider of proprietary, cloud-based analytics, and scientific ... results for the third quarter ended September 30, ... Quarter 2014 Highlights, ,     CannLabs – ... in Las Vegas, Nevada. ,     CannLabs – ...
(Date:11/15/2014)... The "Operating Room Management Market by Product (Data ... operating room Scheduling), by Component (Software, Services), by ... 2019.” defines and segments the operating room management ... by product, such as data management, anesthesia, surgical ... volumes of operating room management market by applications ...
(Date:11/15/2014)... BELLINGHAM, Washington, USA (PRWEB) November 14, 2014 ... enter the SPIE Startup Challenge 2015 , an ... team of business development experts and venture capitalists. The ... at the Moscone Center in San Francisco, running ... society for optics and photonics . , Cash prizes, ...
Breaking Biology Technology:ActiGraph Launches GT9X Link Activity Monitor 2CannLabs Announces Third Quarter 2014 Results. 2CannLabs Announces Third Quarter 2014 Results. 3CannLabs Announces Third Quarter 2014 Results. 4CannLabs Announces Third Quarter 2014 Results. 5Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 2New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 3
... CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and oncology, ... KERX ), its partner and licensee for perifosine in ... the U.S. Food and Drug Administration (FDA) regarding a ...
... ... experiments and trials have given Centre for Jatropha Promotion & Biodiesel (CJP) a big breakthrough ... December 2007. After having a number of successful field trials, CJP is now happy to ... ...
... ... ... -- The future of filling up your tank at home has arrived! The first of ... fuel for cars was installed Thursday night at a home in Pacific Palisades, near Los ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3America's Organic Home-Fueling Movement Begins in Los Angeles 2America's Organic Home-Fueling Movement Begins in Los Angeles 3
(Date:11/6/2014)... when that predator runs so fast that it essentially blinds ... the fastest creature on Earth. Some of these half-inch-long beetles ... miles per hour). The fastest human can do about five ... beetle, a person would have to hit 480 miles per ... peak speeds, everything becomes a blur. They can,t gather enough ...
(Date:11/5/2014)... Rio de Janeiro, Brazil -Individuals show great diversity in ... importantly, males and females greatly differ in their perceptual ... kinds of smell tests. , Sex differences ... social behaviors and may be connected to one,s perception ... and emotions. Thus, women,s olfactory superiority has been suggested ...
(Date:11/4/2014)... (November 4, 2014) — Think about the way our ... do neighboring cells know that they are supposed to ... do these tissues find the correct place and alignment? ... these crucial questions. , In a new study, UM ... communicate with their surrounding neighbors, at the head-trunk region. ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2The female nose always knows: Do women have more olfactory neurons? 2The inside story: How the brain and skull stay together 2
... doesn,t end with the event itself. Blockage of blood flow ... With transplants scarce, half the people who live through a ... address this problem by engineering cardiac tissue to patch up ... Feiner under the supervision of Dr. Tal Dvir of ...
... September 23, 2013 It is often said that ... eliminate their attraction to the abused substance. New findings ... even long-term abstinence from cocaine does not result in ... currently trying to answer some of the ,chicken and ...
... Alliance, a nonprofit organization that focuses on local conservation and ... million award to address land use alteration as a significant ... The funding for the new program was awarded by ... (RDMA). Over 60 percent of emerging infectious diseases over ...
Cached Biology News:Putting the spring back in broken hearts 2Addiction: Can you ever really completely leave it behind? 2EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change 2
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: